Next-Gen Cervical Screening: Integrating Genotyping with Viral Load
Despite decades of progress, cervical cancer remains a leading cause of cancer-related deaths among women globally. Traditional screening methods struggle to balance underscreening gaps and overtreatment risks - a dilemma now addressed by genotype-specific viral load quantification.
Cervical cancer screening is evolving from the qualitative "positive/negative" paradigm to a precision-driven era of genotyping paired with standardized viral load quantification—a dual-strategy approach that redefines clinical decision-making.
Agenda Highlights
11:30 – 11:40 UTC | Welcome & Agenda Overview
11:40 – 12:25 UTC | Expert Talk: Global Trends in HPV Diagnostics
12:25 – 12:35 UTC | Solution Showcase + Genotyping & Quantification Demo
12:35 – 12:50 UTC | Live Q&A Session – Ask the Experts!
Join this exclusive Bioperfectus webinar to learn about this transformative breakthrough in cervical cancer prevention.
About the Speaker
Prof. Pengming Sun, MD, PhD, is a globally recognized leader in HPV detection and cervical cancer prevention, serving as both the Vice President of Fujian Maternal and Child Health Hospital and the Director of Fujian Provincial Clinical Research Center for Gynecological Oncology.
As a core member of the WHO Cervical Cancer Guideline Revision Panel, Prof. Sun’s work aligns with WHO 90-70-90 elimination targets and has been recognized through keynote speeches at IPVC for four consecutive years.
Honored as an Outstanding Contribution Expert and recipient of the Fujian Natural Science Award, Sun bridges the gap between AI innovation and clinical practice, driving transformative solutions in cervical cancer prevention worldwide.
